Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest.

BACKGROUND: Out-of-hospital cardiac arrest (OHCA) frequently occurs in the early phase of acute myocardial infarction (MI). Survivors require percutaneous coronary intervention (PCI) with concomitant dual antiplatelet therapy. Target temperature management, including mild therapeutic hypothermia (MTH), should be applied in comatose patients after resuscitation. However, an increased risk of stent thrombosis in patients undergoing hypothermia is observed. The aim of this study was to assess the impact of MTH on pharmacokinetics of ticagrelor in cardiac arrest survivors with MI treated with MTH and PCI.

METHODS: In a prospective, observational, single-centre study pharmacokinetics of ticagrelor were evaluated in 41 MI patients, including 11 patients after OHCA undergoing MTH (MTH group) and 30 MI patients without OHCA and MTH (no-MTH group). Blood samples were drawn before administration of a180 mg ticagrelor loading dose, and 30 minutes, 1, 2, 4, 6, 12, and 24 hours after the loading dose.

RESULTS: In patients treated with MTH total exposure to ticagrelor during the first 12 hours after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in no-MTH group (AUC(0-12): 3403±2879 vs. 8746±5596 ng·h/mL, difference: 61%, p=0.01; Cmax: 475±353 vs. 1568±784 ng/mL, p=0.0002). Time to achieve maximal ticagrelor plasma concentration was also delayed in MTH group (tmax for ticagrelor: 12 [6-24] vs. 4 [2-12] h, p=0.01).

CONCLUSIONS: Bioavailability of ticagrelor was substantially decreased and delayed in MI patients treated with MTH after OHCA.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02611934.